IMPROVING ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV INFECTION

IMPROVING ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV INFECTION

The objective — to characterize the effectiveness of different schemes of antiretroviral therapy in children with HIV infection and on the basis of the obtained data to improve of the disease treatment.Patients and Methods: A clinical, immunological and virological examination of 45 children with HI...

Full description

Bibliographic Details
Main Authors:	V. B. Denisenko, E. N. Simovanyan
Format:	Article
Language:	Russian
Published:	LLC "Diagnostics and Vaccines" 2018-07-01
Series:	Detskie Infekcii (Moskva)
Subjects:	hiv infection children antiretroviral therapy lopinavir/ritonavir nevirapine
Online Access:	https://detinf.elpub.ru/jour/article/view/362

Similar Items

DYNAMICS OF CLINICAL LABORATORY PARAMETER IN HIV-INFECTED CHILDREN UNDERGOING DIFFERENT PATTERNS OF INITIAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: RANDOMIZED CONTROLLED TRIAL
by: V. B. Denisenko, et al.
Published: (2016-02-01)

Affecting factors to effectiveness of starting therapy in children with hiv infection
by: V. B. Denisenko, et al.
Published: (2015-11-01)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
by: Nils von Hentig, et al.
Published: (2021-05-01)

Combined antiretroviral therapy with nevirapine of HIV-infected adults
by: A V Kravchenko
Published: (2004-11-01)

FIVE-YEAR EXPERIENCE OF HIGHLY ACTIVITY ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV-INFECTION
by: V. B. Denisenko, et al.
Published: (2015-09-01)

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
by: Garren Kevin W, et al.
Published: (2011-05-01)

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV
by: BASAVAPRABHU ACHAPPA, et al.
Published: (2019-01-01)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
by: Bin Su, et al.
Published: (2019-12-01)

Chemical and Toxicological Analysis of Antiretroviral Drugs
by: T. N. Komarov, et al.
Published: (2019-11-01)

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
by: Henri Gautier Ouedraogo, et al.
Published: (2020-01-01)

Farmacocinética da co-formulação Lopinavir/ritonavir em forma de comprimidos, em dosagem padrão e dosagem aumentada, em gestantes portadoras do HIV
by: Oliveira, Marilia Santini de.
Published: (2014)

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China
by: Peng-Le Guo, et al.
Published: (2021-03-01)

Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators
by: A. B. Konkova-Reidman, et al.
Published: (2015-04-01)

Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
by: Xiaojie Huang, et al.
Published: (2019-12-01)

Disposição cinética e transferência placentária do lopinavir e ritonavir em gestantes portadoras do HIV
by: Cestari, Roberta Natália
Published: (2014)

Disposição cinética e transferência placentária do lopinavir e ritonavir em gestantes portadoras do HIV
by: Roberta Natália Cestari
Published: (2014)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Şule Özdemir, et al.
Published: (2020-12-01)

Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital
by: Natsuda Aumpan, et al.
Published: (2021-09-01)

Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
by: Yinqiu Huang, et al.
Published: (2018-08-01)

Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year
by: Audrey Monnin, et al.
Published: (2020-11-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
by: Sanjeev Sinha, et al.
Published: (2017-12-01)

Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1
by: Audrey Monnin, et al.
Published: (2020-09-01)

Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy
by: C Padmapriyadarsini, et al.
Published: (2017-01-01)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
by: Ruxandra-Cristina Marin, et al.
Published: (2021-08-01)

Prevention of Parent to Child Transmission of HIV: Single Centre Experience of 14 years at Tertiary Care Hospital in Delhi, India
by: AG Radhika, et al.
Published: (2017-08-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)
by: Gbenga A. Adefolaju, et al.
Published: (2015-11-01)

Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir
by: Daisy Maria Machado, et al.

Severe Antiretroviral Therapy-Induced Toxic Epidermal Necrolysis in a Child
by: Joseph M. Norris, et al.
Published: (2012-02-01)

Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan
by: Chun-Yuan Lee, et al.
Published: (2017-04-01)

Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan
by: Lee, Chun-Yuan, et al.
Published: (2017)

Mild self-declared side effects of boosted darunavir associated with other antiretrovirals in Romanian HIV-1 infected patients
by: Ruxandra C. MARIN, et al.
Published: (2021-09-01)

Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial
by: Lotfollah Davoodi, et al.
Published: (2021-10-01)

Viral suppression and adherence among HIV‐infected children and adolescents on antiretroviral therapy: results of a multicenter study
by: Maria L.S. Cruz, et al.
Published: (2014-11-01)

HIV Protease Inhibitors Apoptotic Effect in SH-SY5Y Neuronal Cell Line
by: Paola Maura Tricarico, et al.
Published: (2016-09-01)

Comparison of the Efficacy of Sofosbuvir and Kaletra on the Outcome of COVID-19. Is Sofosbuvir A Potential Treatment For COVID-19?
by: Shahnaz Sali, et al.
Published: (2020-12-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
by: Griffith Sandy, et al.
Published: (2003-06-01)

Antiretroviral therapy of acute HIV-infection
by: A V Kravchenko, et al.
Published: (2004-04-01)